Effect Of Complete Decongestive Therapy On Carpal Tunnel Syndrome Post Upper Limb Lymphedema

Lymphedema Clinical Trial

— CDT  

Official title:

Effect Of Complete Decongestive Therapy On Carpal Tunnel Syndrome Post Upper Limb Lymphedema

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05932381
• Other study ID #: P.T.REC/012/003738
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 5, 2023
• Est. completion date: October 5, 2023

Study information

• Verified date: June 2023
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

this study will be conducted to investigate the therapeutic effect of complete decongestive therapy on carpal tunnel syndrome post-upper limb lymphedema.

Description:

lymphedema is a chronic condition characterized by lymphatic vessel ectasia and valve dysfunction, followed by the reflux of lymphatic fluid into the interstitial space. Lymph stasis may lead to a chronic inflammatory process, resulting in adipose tissue differentiation and fibro adipose tissue deposition. One consequence of post-mastectomy lymphedema may be the development of nerve entrapments. One example is median nerve entrapment in the carpal canal, or carpal tunnel syndrome (CTS). many studies assessed the relationship of CTS as a risk factor for developing lymphedema, other studies stated the possibility of lymphedema as a potential contributor to CTS development. Complex decongestive treatment of breast cancer-related lymphoedema is an accepted strategy and is considered as an international standard for treatment. A previous review concluded that complex decongestive therapy has a positive impact on the volume of arm and quality of life in different stages of lymphedema.sixty females will be allocated randomly to two groups; first one will receive decongestive therapy and the second one will receive the routine medical treatment for ten weeks

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: October 5, 2023
• Est. primary completion date: October 5, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

• Age will range between 20- 40 years.

• Only females will participate in the study.

• All patients have carpal tunnel syndrome post upper limb lymphedema.

Exclusion Criteria:

• Diabetes mellitus.

• Individuals with cardiopulmonary conditions.

• Individuals undergoing radiation therapy or chemotherapy.

• Hepatic or pancreatic diseases.

• Sensory impairment.

Related Conditions & MeSH terms

• Carpal Tunnel Syndrome
• Lymphedema

Intervention

Other:
• Complete decongestive therapy
the patients will receive Complete decongestive therapy in the form of intermittent pneumatic compression, Exercising, bandaging, and manual lymphatic drainage with Pressures of 50, 80, and 120 mmHg and timing 5, 20, and 50 secs
• Medical treatment
the patients will receive routine medical treatment

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	hand strength	hand held dynamometer will be used for measuring the hand strength	up to ten weeks
Primary	median nerve conduction velocity	median nerve conduction velocity will be measured by electromyography device	up to ten weeks
Secondary	pain intensity	Visual analogue scale which is 100 mm horizontal line will be used for measuring pain intensity. the scale has no pain on the left side and worst pain on the right side	up to ten weeks